In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone

References

• ATKINS, W. M., WANG, R. W. and Lu, A. Y. H., 2001, Allosteric behavior in cytochrome P450-dependent in vitro drug—drug interactions: a prospective based on conformational dynamics. Chemical Research in Toxicology, 14, 338–347.
   PubMed Web of Science ®Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J, AYRTON, A. D., CLARKE, S. E., CATANESE, B., BARILLARI, G. and GALLI ANGELI, D., 1982, Studies on the oral absorption in man of etoperidone tablets and capsules. Bollettino Chimica Farmaceutico, 121, 530–534.
   PubMedGoogle Scholar
• CALDWELL, G. W., Wu, W. N. and MAsucui, J. A., 2001, Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. Xenobiotica, 31, 823–839.
   PubMed Web of Science ®Google Scholar
• CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, oc-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   Google Scholar
• CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMedGoogle Scholar
• DOMANSKI, T. L., HE, Y. A., KHAN, K. K., ROUSSEL, F., WANG, Q. and HALPERT, J. R., 2001, Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry, 40, 10150–10160.
   PubMed Web of Science ®Google Scholar
• EAGLING, V. A., TJIA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45,107–114.
   PubMed Web of Science ®Google Scholar
• FONG, M. H., Galva-rim, S. and Caccia, S., 1982,1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone, and mepiprazole. Journal of Pharmaceutics and Pharmacology, 34, 674–675.
   Google Scholar
• HYLAND, R., ROE, E. G. H., JONES, B. C. and &virtu, D. A., 2001, Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology, 51, 239–248.
   Google Scholar
• LIN, J. H. and Lu, A. H. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361–390.
   PubMed Web of Science ®Google Scholar
• MAENPAA, J., HALL, S. D., RING, B. J., STROM, S. C. and WRIGHTON, S. A., 1998, Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by oc-naphthoflavone, terfenadine and testosterone. Pharmacogenetics, 8, 137–155.
   PubMedGoogle Scholar
• MAES, M., WESTENBERG, H., VANDOOLAEGHE, E., DEMEDTS, P., WAUTERS, A., NEELS, H. and MELTZER, H. Y., 1997, Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophe-nylpiperazine. Journal of Clinical Psychopharmacology, 17, 358–364.
   PubMed Web of Science ®Google Scholar
• MANCY, A., DIJOLS, S., POLL, S., GUENGERICH, P. and MANSUY, D., 1996, Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry, 35, 16205–16212.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• NGUI, J. S., CHEN, Q., Suou, M., WANG, R. W., STEARNS, R. A., BAILLIE, T. A. and TANG, W., 2001, In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4- and 10-hydroxywarfarin. Drug Metabolism and Disposition, 29, 877–886.
   PubMed Web of Science ®Google Scholar
• NGUI, J. S., TANG, W., STEARNS, R. A., SHOU, M., MILLER, R. R., ZHANG, Y., LIN, J. H. and BAILLIE, T. A., 2000, Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metabolism and Disposition, 28, 1043–1050.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• OTTON, S. V., CREWE, H. K., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1988, Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 247, 242–247.
   PubMed Web of Science ®Google Scholar
• PRAKASH, C., KAMEL, A., Cui, D., WHALEN, R. D., MICELI, J. J. and TWEEDIE, D., 2000, Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. British Journal of Clinical Pharmacology, 49 (suppl. 1), 35S–42S.
   Google Scholar
• PRZEGALINSKI, E. and LEWANDOWSK A., 1979, The effect of etoperidone a new potential antidepressant drug, on the central serotonin system. Journal of Neural Transmission, 46, 303–312.
   PubMed Web of Science ®Google Scholar
• RAFFA, R. B., SHANK, R. P. and VAUGHT, J. L. 1992, Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity. Psychopharmaco/ogy, 108, 320–326.
   PubMedGoogle Scholar
• ROTZINGER, S., FANG, J. and BAKER, G. B., 1998, Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metabolism and Disposition, 26, 572–575.
   PubMed Web of Science ®Google Scholar
• SAI, Y., Dm, R., YANG, T. J., KRAusz, K. W., GONZALEZ, F. J., GELBOIN, H. V. and Sitou, M., 2000, Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica, 30, 327–343.
   PubMed Web of Science ®Google Scholar
• SHOU, M., GROGAN, J., MANCEWICZ, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V. and KORZEKWA, K. R., 1994, Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome p450 active site. Biochemistry, 33, 6450–6455.
   PubMed Web of Science ®Google Scholar
• TANG, W. and STEARNS, R. A., 2001, Heterotropic cooperativity of cytochrome P450 3A4 and potential drug—drug interactions. Current Drug Metabolism, 2, 185–198.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., McMANus, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401–407.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., GRANDA, B. W., GRASSI, J. M., SCHMIDER, J., HARMATZ, J. S. and SHADER, R. I., 1999, Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharma-cology, 145, 113–122.
   PubMedGoogle Scholar
• WANG, R. W., NEWTON, D. J., Liu, N., ATKINS, W. M. and Lu, A. Y. H., 2000, Human cytochrome P-450 3A4: in vitro drug—drug interaction patterns are substrate-dependent. Drug Metabolism and Disposition, 28, 360–366.
   PubMed Web of Science ®Google Scholar
• WU, W. N., CALDWELL, G. W. and UETZ, J. A., 1991, Biotransformation of etoperidone in man. Pharmacologist, 33, 208–212.
   Google Scholar
• WU, W. N., MAsucci, J. A., McKowN, L. A. and RODGERS, J. D., 1995, Identification of four plasma metabolites of etoperidone in dogs. Journal of Pharmaceutics and Biomedical Analysis, 13, 177–184.
   PubMedGoogle Scholar
• WU, W. N. and McKowN, L. A., 2000, Recent advances in biotransformation of CNS and cardiovascular agents. Current Drug Metabolism, 1, 255–270.
   PubMedGoogle Scholar
• WU, W. N. and McKowN, L. A., 2001, In vitro metabolism of etoperidone in human hepatic S9 fraction. Drug Metabolism Reviews, 33, 123.
   Google Scholar
• ZALMA, A., VON MOLTKE, L. L., GRANDA, B. W., HARMATZ, J. S., SHADER, R. I. and GREENBLATT, D. J., 2000, In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biology and Psychiatry, 47, 655–661.
   PubMed Web of Science ®Google Scholar
• ZHOU, S., PAXTON, J. W., TINGLE, M. D. and KESTELL, P., 2000, Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metabolism and Disposition, 28, 1449–1456.
   PubMed Web of Science ®Google Scholar